Latest Breaking News On - Pharmaceuticals division - Page 6 : comparemela.com

First Patient Randomized in AskBio Phase II Gene Therapy Trial for Congestive Heart Failure Treatment

Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a subsidiary of Bayer AG, have announced that the first patient has been randomized in GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase II trial of AB-1002, also known as NAN-101, for the treatment of congestive heart failure (CHF).

United statesTimothyd henryChristian rommelRogerj hajjarHead of researchAmerican heart association scientific sessionsYork heart associationBayer agAsklepios biopharmaceutical incSteering committee memberAsklepios biopharmaceuticalInhibition therapyNew york heart associationPrincipal investigatorSteering committeeHeart failure awareness week

First Patient Randomized In Askbio Phase II Gene Therapy Trial For Congestive Heart Failure

First Patient Randomized In Askbio Phase II Gene Therapy Trial For Congestive Heart Failure
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

University of north carolinaNorth carolinaUnited statesPais vascoResearch triangle parkUnited kingdomCity ofChristian rommelAnn pentecost bayerTimothyd henryR jude samulskiRogerj hajjarJosh griegerPhil mcnamara askbioSpanish agency for medicinesTechnology park

Vividion Therapeutics, Inc : Vividion Therapeutics starts Phase I clinical trial in advanced solid and hematologic tumors with oral STAT3 inhibitor

Vividion Therapeutics, Inc : Vividion Therapeutics starts Phase I clinical trial in advanced solid and hematologic tumors with oral STAT3 inhibitor
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Laurie shermanLisa hennigStefan klotterAleksandra rizoChristian rommelJenna goldbergVividion therapeutics incHead of researchBayer agChief executive officerExecutive committeePharmaceuticals divisionChief medical officerMedia contactDie performance strategieAssets sie

Vividion Therapeutics starts Phase I clinical trial in advanced solid and hematologic tumors with oral STAT3 inhibitor

BERLIN & SAN DIEGO (BUSINESS WIRE) Feb 6, 2024

United statesJenna goldbergLaurie shermanAleksandra rizoLisa hennigChristian rommelBayer agVividion therapeutics incHead of researchChief executive officerExecutive committeePharmaceuticals divisionChief medical officerVividion media contactMedia contactVividion therapeutics

Bradley Williams Joins Bayer Thai as Managing Director and Leads Pharmaceuticals Division

Bradley Williams has been appointed as Managing Director of Bayer Thai Co., Ltd and Country Division Head of Pharmaceuticals. The appointment takes effect from February 1, 2024. He will be responsible for overseeing overall development and business

New south walesBradley williamsUniversity of western sydneyPharmaceuticals divisionBayer thai co ltdCountry division head of pharmaceuticalsAbbott laboratoriesManaging directorCountry division headWilliams joins bayer thaiLeads pharmaceuticalsGlaxo wellcomeBayer australiaBusiness unit headSpecialty medicineCommerce degree